Christine Lovly

Nashville

Featured in: Favicon

wiley.com

nature.com Favicon

biomedcentral.com Favicon

medscape.com Favicon

healio.com Favicon

aacrjournals.org Favicon

onclive.com Favicon

targetedonc.com Favicon

onlinelibrary.wiley.com Favicon

molecular-cancer.biomedcentral.com + 1 more

Articles

Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study

Jun 1, 2024 | brnw.ch | Christine Lovly

Published In Journal of Clinical Oncology: JCO.24.00731HistoryPublished online: June 01, 2024PermissionsRequest permissions for this article. Clinical trial data can be requested by qualified researchers for use in rigorous, independent scientific research as long as the trials are not part of an ongoing or planned regulatory submission. Sharing of data is subject to protection of patient privacy and respect for the patient's informed consent.
Dr Lovly on the Investigation of BDTX-1535 in NSCLC

May 31, 2024 | onclive.com | Christine Lovly

CommentaryVideoMay 31, 2024Author(s):Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer. Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer (NSCLC).
Refining neoadjuvant immunotherapy for resectable lung cancer - Nature Medicine

May 13, 2024 | nature.com | Christine Lovly

In an era of expanding perioperative approaches for resectable non–small-cell lung cancer, new data demonstrate that dual neoadjuvant immunotherapy targeting PD-1 and LAG-3 is feasible; future analyses may enhance patient selection by identifying immune signatures predictive of response.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis - Nature Communications

Mar 26, 2024 | nature.com | Pooja Middha |Michael Betti |Cosmin Bejan |Douglas Johnson |Linda Kachuri |Christine Lovly | +4 more

AbstractImmune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) predisposes to IMC.
Strategies to Overcome Resistance to ALK Inhibitors in NSCLC

May 22, 2023 | medscape.com | Aakash Desai |Christine Lovly

Abstract and Introduction Abstract Background and Objective: Anaplastic lymphoma kinase (ALK) rearrangements are detected in 3–7% of advanced non-small cell lung cancer (NSCLC). There are currently 5 U.S Food and Drug Administration (FDA)-approved ALK tyrosine kinase inhibitors (TKIs) for the treatment of patients with ALK-positive lung cancer in the advanced/metastatic disease setting.